On Wednesday, Johnson & Johnson's (JNJ, Financial) stock opened with a nearly 4% decline, marking its largest drop since July 2023, currently priced at $142.53. The company reported fourth-quarter sales of $22.52 billion, a 5.3% increase year-over-year, surpassing market expectations of $22.43 billion.
However, the adjusted earnings per share for the fourth quarter were $2.04, down from $2.29 in the previous year, though slightly above the forecast of $1.99. Looking ahead, Johnson & Johnson anticipates fiscal year 2025 sales growth between 0.5% and 1.5%, with total sales projected to range from $89.2 billion to $90 billion. This projection falls short of analysts' current estimates of $90.98 billion, according to FactSet.
The company noted that without the impact of acquisitions, divestitures, and foreign exchange fluctuations, sales figures would have been higher.
